GMIP

Across TCGA pan-cancer cohorts, GMIP Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated GMIP data layer compared with 27 for mass-spec protein and 2 for mass-spec protein.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher GMIP Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated GMIP expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

STAD, COAD, and UCEC are the cancer types where GMIP Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	OS	Median	III,IV	0.003	0.633	<.001	16	view →
COAD	OS	Median	All	0.594	0.872	.007	5	view →
UCEC	DFS	Median	All	0.927	0.619	.019	4	view →
SARC	DFS	Median	All	0.098	0.591	.010	3	view →
ACC	DFS	Median	All	0.195	0.748	.003	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

GMIP–STAD (OS)

Open the STAD breakdown →